Abstract:Cystic fibrosis (CF) is a genetic disorder caused by mutations in the *CFTR* gene, leading to severe respiratory and digestive problems. Current therapies including AAV gene therapy, small molecule modifiers, and RNA-based therapies only partially restore *CFTR* function, leaving a need for more effective therapies The aim of this review is to address CRISPR-1. Cas9-mediated genetic correction in patient derived lung organoids Efficacy, safety and long-term outcomes are evaluated as a novel strategy for CF therapy. Our goal was to achieve high gene editing efficiency, restore *CFTR* function to near normal levels, and evaluate the safety of this approach by monitoring off-target effects CRISPR-Cas9 achieved 75% average gene editing efficiency, with recovery of *CFTR* function up to 85%, AAV gene therapy (35% efficiency, 50). % Functional restoration), small molecule modulators (60% functional restoration), and... RNA-based therapy (57% functional restoration). Off-target effects were small, observed at 0.5%, confirming the accuracy of CRISPR-Cas9 in correcting *CFTR* mutations. The use of patient-derived lung organoids proved important for modeling the ailment and trying out healing interventions, providing excessive personalization ability and the cap potential to reveal long-time period stability. The look at concludes that CRISPR-Cas9, while carried out to patient-derived lung organoids, represents a promising development withinside the remedy of Cystic Fibrosis, providing advanced efficacy and personalization as compared to present methods. However, the excessive fee and moral concerns related to CRISPR-Cas9 necessitate similarly studies to optimize its utility and make sure its protection in medical settings.

Gene Editing and Genetic Lung Disease. Basic Research Meets Therapeutic Application

Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders

How can gene editing of human pluripotent stem cells help understand the effect of genetics on respiratory diseases?

Gene editing using CRISPR-Cas9 for the treatment of lung cancer

CRISPR/Cas9 gene editing therapies for cystic fibrosis

In utero gene editing for monogenic lung disease

Applications of CRISPR systems in respiratory health: Entering a new 'red pen' era in genome editing

Gene editing as a promising approach for respiratory diseases.

A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency

CRISPR-Cas9 Mediated Gene Correction of CFTR Mutations in Cystic Fibrosis: Evaluating Efficacy, Safety, and Long-Term Outcomes in Patient-Derived Lung Organoids

Shaping the future from the small scale: dry powder inhalation of CRISPR-Cas9 lipid nanoparticles for the treatment of lung diseases

CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer

Gene Therapy in Rare Respiratory Diseases: What Have We Learned So Far?

CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders

Development and application of CRISPR/Cas9 technologies in genomic editing.

AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway

In vivo editing of lung stem cells for durable gene correction in mice

Application of CRISPR gene editing technology in cystic fibrosis treatment

Progress in Respiratory Gene Therapy

Induced Pluripotent Stem Cells and CRISPR-Cas9 Innovations for Treating Alpha-1 Antitrypsin Deficiency and Glycogen Storage Diseases

CRISPR-Cas9-mediated gene therapy in lung cancer